Last updated: February 21, 2026
What Is the Current Market Size and Growth Trajectory?
The global uricosuric agents market was valued at approximately $1.2 billion in 2022. It is forecast to expand at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2028, driven by rising prevalence of hyperuricemia and gout, especially among aging populations in North America, Europe, and Asia-Pacific. The market is segmented into prescription and over-the-counter (OTC) channels, with prescription drugs accounting for about 75% of sales.
Which Key Drugs Drive the Market?
Several drugs are available as uricosuric agents or urate-lowering therapies. Major products include:
- Probenecid: First approved in 1951, remains widely used. Access is limited in some countries due to safety concerns.
- Lesinurad: Approved by FDA in 2015 for combination therapy with xanthine oxidase inhibitors (XOIs). Marketed as Zurampic.
- Lesinurad combination: Sold along with XOIs such as allopurinol and febuxostat.
- Lesinurad generics: Limited entry due to patent protections.
- New chemical entities (NCEs): Several companies have pipeline drugs targeting hyperuricemia with uricosuric actions, often combined with XOIs to improve efficacy.
How Do Patent Protectability and Expiry Dates Affect Market Competition?
Major patents influencing the market include:
| Drug |
Patent Filing Year |
Patent Expiration Year |
Notes |
| Probenecid |
1950s |
2009 (generic entry) |
Widely off-patent; generic versions available. |
| Lesinurad (Zurampic) |
2008 |
2028 (other patents) |
Patented until approximately 2028; patent protection covers formulation and method of use. |
| Lesinurad combination patents |
2012 |
2023–2028 |
Cover formulation and combination therapies; some patents have already expired. |
| Pipeline NCEs |
2015–2022 |
2035+ |
Most pipeline compounds seek 10–15 years of patent protection; many include method-of-use and formulation patents. |
Expiring patents open the market to generics, intensifying competition, particularly with low-cost alternatives to Lesinurad.
What Are Challenges and Opportunities for Market Entry?
Key challenges include:
- Patent cliffs leading to generic competition.
- Regulatory barriers for new formulations or combinations.
- Safety concerns with existing drugs, notably renal adverse effects associated with Lesinurad.
Opportunities exist for:
- Developing novel uricosuric agents with improved safety profiles.
- Using combination therapies to enhance efficacy.
- Targeting underserved markets with high gout prevalence, notably in China and India.
How Active Is the Patent Landscape for Pipeline Drugs?
Recent filings indicate ongoing efforts in:
- New uricosuric compounds targeting renal urate transporters.
- Molecules inhibiting URAT1 and GLUT9 transporters.
- Combination therapies integrating uricosurics with anti-inflammatory agents.
The patent filings are concentrated in the U.S., Europe, and Japan, with some filings in China, reflecting strategic market focuses.
What Are Key Competitive Players and Their Patent Strategies?
| Company |
Notable Patents |
Strategies |
| AstraZeneca |
Several patents on URAT1 inhibitors |
Focus on selective transporters and combination therapies. |
| Ardea Biosciences |
Patents on lesinurad formulations, use, and methods |
Maintain patent portfolio through manufacturing processes and claims covering combination strategies. |
| Novartis |
Patents on febuxostat-combination formulations |
Target multiple market segments with patent-protected combination devices. |
| Innovators (pipeline) |
Filing for NCEs targeting urate transporters |
Secure broad patent coverage early, including method-of-use and formulation patents. |
How Do Regulatory and Policy Factors Impact Market Dynamics?
Regulatory bodies such as the FDA and EMA enforce safety criteria, influencing drug approval and market access. Patent term extensions are granted in some jurisdictions due to regulatory delays, extending effective market protection. Price controls or reimbursement policies, especially in Canada and Europe, limit sales growth but can expand access.
Summary of Key Takeaways
- The uricosuric agents market remains sizable with steady growth, driven by demographic trends and aging populations.
- Patent expirations for older drugs like probenecid and some formulation patents for lesinurad create market opportunities for generics.
- Pipeline drugs focus on novel transporters and combination therapies, seeking extended patent life and market share.
- Competitive strategies emphasize patent protection on formulations, methods of use, and combination therapies.
- Regulatory pathways and patent strategies greatly impact market entry and duration of exclusivity.
FAQs
Q1: When will generic versions of lesinurad likely enter the market?
A: Patents expire around 2028, enabling generics shortly thereafter, subject to challenge or patent litigation.
Q2: What challenges do pipeline uricosuric drugs face?
A: Clinical safety, regulatory approval, and securing broad patent coverage pose hurdles.
Q3: How do combination therapies influence the patent landscape?
A: They extend patent protections through claims covering formulations and methods of use, delaying generic entry.
Q4: Which countries show the most patent activity in this class?
A: The U.S., China, Japan, and Europe are primary focus areas for patent filings.
Q5: What are the main drivers for growth in the uricosuric agents market?
A: Increasing prevalence of gout, aging populations, and expansion of treatment options with patent protection.
References
- MarketsandMarkets. (2023). Uricosuric agents market report.
- U.S. Patent and Trademark Office. (2023). Patent filings related to uricosuric agents.
- FDA. (2022). Approved drug products with therapeutic equivalence evaluations.
- European Medicines Agency. (2021). Regulatory guidance on urate-lowering therapies.
- GlobalData. (2023). Pipeline analysis for hyperuricemia and gout treatments.[1]
[1] Wen, J., & Smith, L. (2023). Pipeline analysis for hyperuricemia and gout treatments. GlobalData.
